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Objective: To evaluate the prognosis after esophagectomy for squamous cell carcinoma of the thoracic esoph-
agus and its prognostic factors.
Methods: Six hundred five patients with primary squamous cell carcinoma of the thoracic esophagus who un-
derwent curative esophagectomy between June 1997 and June 1998 were collected from 3 medical centers.
Among them, 26 patients died from the operation and 26 patients did not complete adjuvant treatment owing
to toxicity. Univariate and multivariate analysis was performed to identify prognostic factors for survival. The
effect of adjuvant treatment on survival was also evaluated.
Results: The 1-, 3-, 5-, and 10-year overall survivals of 605 patients were 90%, 65%, 36%, and 8%, respec-
tively. Multivariate analysis identified the following as independent prognostic factors: number of lymph node
metastases (P< .001), histologic differentiation (P< .001), tumor location (P ¼ .002), depth of invasion (P ¼
.020), and vascular invasion (P ¼ .023).
Conclusions: Several pathologic characteristics of the primary tumor are correlated with the outcome of esoph-
agectomy for squamous carcinoma of the thoracic esophagus. Patients with fewer than 2 metastatic nodes after
curative esophagectomy have a better prognosis than those with multiple involved nodes (>2). To stratify patients
appropriately for prognosis, it is necessary to refine the current 6th edition TNM staging system.In China, there is an increased prevalence of esophageal can-
cer, most of which consists of squamous cell carcinoma
(SCC). This is in contrast to the dominant trend toward
adenocarcinoma in the Western world. The long-term
outcomes for selected patients undergoing multimodality
treatment, which combines surgery with chemotherapy
and radiation, are promising. In this study, we collected
data on 605 patients who had received multimodality ther-
apy for esophageal cancer from 3 regional medical centers
and retrospectively evaluated outcomes to identify prognos-
tic factors leading to improved survival.1
PATIENTS AND METHODS
From June 1997 to June 1998, 712 patients with primary SCC of the tho-
racic esophagus were admitted to our regional thoracic surgical centers
(Jiangsu Province Tumor Hospital, Jiangsu Province People’s Hospital
[Nanjing Medical University] and Nanjing Jiangbei People’s Hospital
[Dongnan University]). Among them, 605 patients underwent en bloc rad-
ical esophagectomy through a left thoracotomy, with a 2-field lymph node
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doi:10.1016/j.jtcvs.2008.05.024The Journal of Thoracic anddissection in the mediastinum and upper abdomen. Reconstruction con-
sisted of a gastric tube placed through the posterior mediastinum, and esoph-
agogastrostomy was performed via a left cervical incision.
Postoperatively, the pathologic status of the resected tumors was evalu-
ated to determine the need for adjuvant treatment. Patients with superficial
cancer and no lymph node involvement underwent no further treatment.
Those with tumor invading past the submucosa or with lymph node involve-
ment were routinely administered chemotherapy and radiation. Chemother-
apy consisted of 2 cycles: a bolus administration of cisplatin (20 mg/m2 per
day) occurred on days 1 to 3, and fluorouracil (500 mg/m2 per day) was
given as a continuous infusion over 24 hours on days 1 to 5. Postoperative
radiotherapy was administered by linear accelerators with 10- to 15-MV
photons. Radiotherapy was simulated to encompass a tumor volume with
5-cm cephalocaudal margins and 2-cm radial margins. Treatment ports
were designed to encompass enlarged regional nodes and metastatic nodal
beds based on preoperative computed tomographic evaluation and postop-
erative pathologic examination. Radiation was delivered in daily fractions
of 1.8 Gy with a total dose of 50 to 60 Gy using a multiple-field technique.
Pathologic examination of the resected surgical specimens followed
a standardized protocol. First, 4-mm sections of the tumor were stained
with hematoxylin and eosin. The total number of lymph nodes resected
and the number of lymph nodes involved with tumor were recorded. Vascu-
lar invasion was defined as infiltration of vessels or the presence of tumor
emboli. Resection was considered microscopically incomplete when tumor
cells were present less than 1 mm from the plane of resection (ie, the circum-
ferential margin). The degree of tumor differentiation was classified as well,
moderately, and poorly differentiated. Tumor staging occurred according to
the pTNM system established by the International Union Against Cancer
(UICC) in 2002 (6th edition).1
Postoperative patients were surveyed every 3 months by physical exam-
ination, every 6 months by imaging (computed tomographic scan and
abdominal ultrasound), and every year by esophagoscopy. The study proto-
col was approved by the regional institutional review board. All patients
provided written informed consent.
Statistical Methods
Continuous data were presented as mean values with standard deviations
(mean  SD). Means were compared with the Mann–Whitney test.Cardiovascular Surgery c Volume 137, Number 1 55
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pM ¼ presence of metastasis
pN ¼ lymph node metastases
pT ¼ depth of tumor invasion
SCC ¼ squamous cell carcinoma
UICC ¼ International Union Against Cancer
Categorical data were compared with a c2 test (with the Yates correction) or
the Fisher exact test. Follow-up continued until December 2007 or death if
earlier. Overall survival was evaluated by the Kaplan–Meier method and
included perioperative deaths. Overall survivals were compared by the
log–rank test. Multivariate analyses were performed by Cox regression.
To evaluate the optimal cutoff point for the number of involved nodes as
a predictor for survival, we delineated the relationship between the number
of positive nodes and survival using a scatterplot of the variable versus
Martingale residuals from a Cox proportional hazards regression model
without the variable of interest. A smoothed fit of the scatter was then
applied to detect the optimal cutoff point.2
All statistical tests were 2-sided. Statistical significance was set at the
5% level. Calculations were performed with SPSS version 12.0.1 (SPSS,
Inc, Chicago, Ill).
RESULTS
A total of 605 patients (male/female: 512/93; age: 63.0 
9.3 years) underwent en bloc radical esophagectomy. The
median length of hospital stay was 15.8 days (range 10–
156 days), and 26 (4.3%) patients died as a result of the op-
eration (male/female: 23/3; age: 63.7 11.9 years). Another
26 patients (male/female: 21/5; age: 58.8  12.5 years) did
not complete adjuvant therapy owing to nephrotoxicity,
gastrointestinal adverse reactions, and myelosuppression.
Therefore, the other 553 patients (male/female: 468/85;
age: 61.2  10.1 years) completed the proposed chemora-
diation treatment.
Overall Survival
Follow-up was complete for all 605 patients. The median
follow-up was 47.0 months. At the time of this analysis, the
1-, 3-, 5-, and 10-year overall survivals of the 605 patients
were 90%, 65%, 36%, and 8%, respectively, with a median
survival of 79.2 months.
The 1-, 3-, 5-, and 10-year disease-specific survivals for
stage 0 (n ¼ 30) were 100%, 100%, 90%, and 80%; for
stage I (n ¼ 78), 99%, 95%, 85%, and 58%; for stage IIa
(n ¼ 111), 99%, 88%, 65%, and 34%; for stage IIb (n ¼
165), 95%, 73%, 48%, and 18%; for stage III (n ¼ 185),
92%, 67%, 44%, and 9%; and for stage IV (n ¼ 36),
85%, 35%, 19%, and 0 (log–rank test; P< 0.001) (Fig-
ure 1).
Factors Influencing Survival
Apart from pT (depth of tumor invasion), pN (lymph node
metastases), and pM (presence of metastasis), univariate56 The Journal of Thoracic and Cardiovascular Surganalysis identified the following variables as significant pre-
dictors of survival: tumor location, histologic differentiation,
vascular invasion, and number of lymph node metastases
(Table 1). Age, gender, tumor length, total number of
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FIGURE 1. Cumulative disease-specific survival curves in terms of tumor
pTNM stage. Median survival time for patients with stage 0 (n¼ 30), stage
I (n¼ 78), stage IIa (n¼ 111), stage IIb (n¼ 165), stage III (n¼ 185), stage
IV (n ¼ 36) were 130.0, 130.0, 112.4, 60.8, 49.7, and 26.2 months, respec-
tively (log–rank test, P< .001).
TABLE 1. Clinicopathologic features influencing disease-specific
survival of 605 patients
Survival (%)
Variable No. 1 y 3 y 5 y 10 y P
Depth of invasion*
pTis 30 100 100 90 80 <.001
pT1 139 98 90 74 51
pT2 171 96 77 57 29
pT3 164 94 68 42 8
pT4 101 88 58 37 8
Tumor location
Upper 175 92 59 33 13 <.001
Middle 227 96 78 57 23
Lower 203 96 86 68 31
Histologic differentiation
Well 164 96 88 75 44 <.001
Moderate 159 94 79 62 32
Poor 189 94 69 41 13
Undifferentiated 93 94 55 29 0
Vaso-invasive growth
Not marked 364 96 79 58 31 <.01
Marked 241 92 69 49 11
No. of lymph node
metastases
0 156 99 93 77 43 <.001
12 239 97 82 63 23
3 87 91 74 41 0
>3 123 88 39 12 0
*Classification of primary tumor and TNM staging according to TMN classification
(6th edition, 2002).ery c January 2009
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Sdissected lymph nodes, and time of operation did not influ-
ence the survival (data not shown).
Cumulative disease-specific survival curves in terms of
tumor location, histologic differentiation, and vascular inva-
sion are shown in Figures 2, 3 and 4, respectively. So that the
optimal cutoff point for the number of positive lymph nodes
could be determined, the Martingale residuals of the Cox
model were first calculated and then plotted against the num-
ber of positive nodes (not shown). The cutoff value was 3
positive nodes. Subdivision of pN stage into 4 groups based
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FIGURE 2. Cumulative disease-specific survival curves in terms of tumor
location. Median survival time for patients with upper thoracic cancer (n ¼
175), middle thoracic esophageal cancer (n ¼ 227), and lower thoracic
esophageal cancer (n¼ 203) were 45.9, 82.2, and 93.8 months, respectively
(log–rank test, P< .001).
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FIGURE 3. Cumulative disease-specific survival curves in terms of histo-
logic differentiation of tumor. Median survival time for patients with well
(n ¼ 164), moderate (n ¼ 159), poor (n ¼ 189), and undifferentiated
(n ¼ 93) were 111.6, 86.7, 54.0, and 43.1 months, respectively (log–rank
test; P< .001).The Journal of Thoracic andon the number of positive nodes (0, 1–2, 3, and 4 nodes
positive) showed significant differences in disease-specific
survival. For these groups, median survival times were
119.7 (n ¼ 156), 90.4 (n ¼ 239), 51.6 (n ¼ 87), and 32.7
(n ¼ 123) months, respectively (log–rank, P< .001). Fig-
ure 5 shows that patients with 2 involved lymph nodes or
fewer have a longer disease-specific survival than do those
with more significant nodal disease (3 positive nodes).
Multivariate analysis identified the following as indepen-
dent prognostic factors: the number of lymph node metasta-
ses (P< .001), histologic differentiation (P<0.001), tumor
location (P ¼ .002), depth of invasion (P ¼ .020), and vas-
cular invasion (P ¼ .023) (Table 2).
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FIGURE 4. Cumulative disease-specific survival curves in terms of vaso-
invasive growth of tumor. Median survival time for patients with negative
(n ¼ 358) and positive (n ¼ 247) were 84.6 and 61.3 months, respectively
(log-rank test; P< .01).
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FIGURE 5. Cumulative disease-specific survival curves in terms of num-
ber of lymph node (LN) metastases (log–rank test; P< .001).Cardiovascular Surgery c Volume 137, Number 1 57
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ing the TNM stage of the disease as a covariate. We ex-
cluded the pT factor and the number of involved lymph
nodes for a more appropriate analysis of independent prog-
nostic factors. In this additional analysis, vascular invasion
no longer appeared as an independent prognostic factor for
increased survival (P ¼ .073).
To investigate the role of postoperative chemoradiation
on survival after esophagectomy, we excluded the 26 pa-
tients who died perioperatively. The remaining 579 patients
were divided into 3 groups: those who completed adjuvant
treatment after surgery (n ¼ 449), those who did not com-
plete adjuvant treatment (n ¼ 26), and those for whom adju-
vant treatment was not recommended owing to early disease
(n ¼ 104). Figure 6 shows the improved survival in the
group who completed adjuvant treatment, in contrast to
that in the group who did not complete treatment.
DISCUSSION
Radical esophagectomy has become the standard surgical
procedure to achieve an accurate pathologic staging for pa-
TABLE 2. Multivariate analysis of prognostic factors for disease-
specific survival by the Cox proportional hazard model
Parameter* Coefficient P Hazard 95% CI
Tumor location .243 .002 .784 0.674–0.911
Depth invasion .183 .020 1.201 1.030–1.401
Involved lymph node .373 <.001 1.453 1.359–1.553
Histologic differentiation .502 <.001 1.653 1.480–1.845
Vasoactive growth .261 .023 1.298 1.037–1.625
CI, Confidence interval. *Parameters are categorized in Table 1.
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FIGURE 6. Cumulative disease-specific survival curves in terms of post-
operative adjuvant radiochemotherapies for the patients with SCC of the
thoracic esophagus (n ¼ 579). The 1-, 3-, 5- and 10-year disease-specific
survivals for the unnecessary postoperative radiochemotherapy patients (n
¼ 104) were 99%, 96%, 88%, and 63%; for the completed postoperative
radiochemotherapy patients (n ¼ 449) were 95%, 72%, 49%, and 17%;
and for the incompleted patients (n¼ 26) were 77%, 56%, 20%, and 0; re-
spectively (log–rank [Mantel–Cox]; P< .001).58 The Journal of Thoracic and Cardiovascular Surgtients with esophageal cancer,3,4 but the long-term outcomes
are not necessarily satisfactory according to the UICC–TNM
staging.4,5 In this study, we collected a well-defined homo-
geneous cohort of 605 patients with SCC of the thoracic
esophagus and evaluated the long-term outcomes to identify
prognostic factors. Given that the data were retrospective,
our conclusions are limited. Our findings are interpreted
within the context of existing published data.
Esophageal Cancer Located in the Upper Thorax Is
an Unfavorable Prognostic Factor
One hundred twenty-nine of 175 patients with upper tho-
racic cancer who died had locoregional recurrences in the
upper mediastinum despite extensive lymphadenectomy.
Locoregional recurrence consisted of progression of medias-
tinal nodal disease, including direct invasion into the tra-
cheobronchial trees. More meticulous lymphadenectomy
around the tracheobronchial trees and bilateral recurrent
laryngeal nerves may be important to improve the outcomes
of these patients.3
Patients with Esophageal Cancer Achieved Improved
Survival after Multimodality Therapy
All 605 patients underwent left thoracotomy with 2-field
lymph node dissection in the mediastinum and upper abdo-
men. Including those patients who underwent adjuvant che-
moradiation, the 3- and 5-year overall survivals were 65%
and 36%. Previous studies in the existing literature show ex-
cellent results with a surgical approach that includes 3-field
lymphadenectomy. Such an approach likely has the highest
chance of tumor clearance,5,6 but this is at the expense of in-
creased morbidity and mortality and poorer postoperative
quality of life.4 Our study suggests that patients who success-
fully completed adjuvant treatment had an increased survival
comparedwith thosewhodid not complete the treatment.Ran-
domized studies with larger cohorts of patients are needed to
further evaluate the effect of adjuvant chemoradiation.
UICC–TNM Staging of Esophageal Cancer Needs to
be Refined
The TNM system for classifying the anatomic extent of
disease in cancer has been in existence for more than 50
years. In this study, we evaluated additional prognostic fac-
tors in a homogeneous group of patients with esophageal
cancer treated by multimodality therapy. Our study con-
firmed that the pT and pN stages according to the 6th edition
UICC–TNM staging model are indeed important predictors
of survival.
However, there is ongoing debate about the need for revi-
sion of the current guidelines, driven by surgeons who be-
lieve that the current system does not accurately stratify
patients for prognosis.7-9 Recently, the UICC–TNM com-
mittee decided to establish guidelines for the submission
and evaluation of proposed changes to the TNM system.10ery c January 2009
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SIn our study, other pathologic characteristics of the primary
tumor, including tumor location, histologic differentiation,
and vascular invasion, were shown to correlate with out-
come. Such pathologic criteria as histologic differentiation
and vascular invasion represent the biological property of
the tumor and should be considered in the modified staging
system.
Moreover, survival is influenced not only by the presence
or absence of involved lymph nodes (pN0 vs pN1) but also
by the number of positive nodes. In our study, subdivision of
pN1 tumors into pN12, pN3, and pN4 had significant
differences in survival. These findings are similar to obser-
vations made by Rice and associates,7 who subclassified
their node-positive patients as N1 (2 metastatic nodes)
and N2 (3 metastatic nodes) on the basis of significantly
different survivals. Generally, patients with more advanced
nodal disease had worse survival than those with less nodal
disease (eg, 1–3 vs 4, 1–4 vs 5).5,11 Published studies
thus far differ in the calculations by which the optimal cutoff
for the number of positive nodes is determined. By calculat-
ing the Martingale residuals, we found that the cutoff should
be 3 positive nodes. The patients with fewer than 2 meta-
static nodes had improved long-term survival; this was an in-
dependent and favorable prognostic factor. Similar data have
been reported for adenocarcinoma of the esophagus.12 Thus,
patients with fewer than 2 metastatic nodes after esophagec-
tomy have an improved prognosis compared with those with
more advanced nodal disease. This suggests that more ag-
gressive adjuvant therapy may be the key to improve the sur-
vival of patients with multiple lymph node metastases.
Within the group of patients with positive locoregional
nodes, a further subdivision can be made on the basis of
the number of positive nodes divided by the total number
of resected nodes, also known as the lymph node ratio.13,14
Various lymph node ratios have been proposed13-15 owing to
differences in the techniques of lymphadenectomy and the
total number of resected nodes.2 In our patients, lymph
node dissection includes the superior, middle, and inferior
mediastinum and around the splenic, celiac, and hepatic ar-
teries. About 10 to 17 nodes (a median number of 14) were
resected for each patient. The total number of resected nodes
was not associated with differences in overall survival. Thus
this may suggest that lymph node ratio may not be an inde-
pendent factor. However, more studies are needed to con-
firm this finding.
So that patients can be better stratified according to prog-
nosis, the current 6th edition TNM staging system for esoph-
ageal cancer must be revised. We would suggest that
pathologic criteria such as histologic differentiation and vas-
cular invasion be incorporated into the new staging systemThe Journal of Thoracic andinasmuch as our study showed these to be independent
prognostic factors in patients who underwent multimodal
treatment of esophageal cancer. We look forward to the
modification of the UICC–TNM staging system with clini-
copathologic variables that are confirmed to be independent
prognosticators in further studies and large randomized
trials.
CONCLUSION
Several pathologic characteristics of the primary tumor
are correlated with differences in long-term outcomes after
esophagectomy for SCC of the thoracic esophagus. Patients
with fewer than 2 metastatic nodes after radical esophagec-
tomy have a better prognosis than those with multiple in-
volved nodes (>2).
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